Sonnet BioTherapeutics Holdings, Inc.

Contributing Author

Recent Articles by Sonnet BioTherapeutics Holdings, Inc.

Dec-02	Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination GlobeNewswire
Dec-02	Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc GlobeNewswire
Nov-18	Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting GlobeNewswire
Sep-19	Sonnet to Present at the MedInvest Biotech & Pharma Conference GlobeNewswire
Aug-11	Sonnet Releases Virtual Investor "What This Means" Segment GlobeNewswire
Aug-04	Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer GlobeNewswire
Jul-14	Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy GlobeNewswire
May-01	Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit GlobeNewswire